The AAPS Journal

, Volume 15, Issue 3, pp 893–896 | Cite as

Evaluation of Pre-existing Antibody Presence as a Risk Factor for Posttreatment Anti-drug Antibody Induction: Analysis of Human Clinical Study Data for Multiple Biotherapeutics

Rapid Communication


Biotherapeutic-reactive antibodies in treatment-naïve subjects (i.e., pre-existing antibodies) have been commonly detected during clinical immunogenicity assessments; however information on pre-existing antibody prevalence, physiological effects, and impact on posttreatment anti-drug antibody (ADA) induction remains limited. In this analysis, pre-existing antibody prevalence and impact on posttreatment ADA induction were determined using ADA data from 12 biotherapeutics analyzed in 32 clinical studies. Approximately half (58%) of the biotherapeutics were associated with some level of pre-existing antibodies and 67% of those were associated with posttreatment ADA induction. Across all studies, 5.6% of study subjects demonstrated presence of pre-existing antibodies, among which, 17% of the individual subjects had posttreatment increases in their ADA titers while 16% had decreased titers and 67% had no change in titers. However, in studies conducted in the rheumatoid arthritis (RA) population, 14.8% of RA patients were associated with pre-existing antibodies and 30% of those had posttreatment titer increases. The results suggest that in most study subjects, pre-existing antibodies pose a low risk for posttreatment ADA induction. That said, the high risk of induction implicated for RA patients, primarily observed in treatments evaluating novel antibody-based constructs, indicates that further understanding of the contribution of product and disease-specific factors is needed. Cross-industry efforts to collect and analyze a larger data set would enhance understanding of the prevalence, nature, and physiological consequences of pre-existing antibodies, better inform the immunogenicity risk profiles of products associated with these antibodies and lead to better fit-for-purpose immunogenicity management and mitigation strategies.

Key words

anti-drug antibodies immunogenicity risk pre-existing antibodies 


  1. 1.
    Ballard JL, Weaver FA, Singla NK, et al. Safety and immunogenicity observations pooled from eight clinical trials of recombinant human thrombin. J Am Coll Surg. 2010;210(2):199–204.PubMedCrossRefGoogle Scholar
  2. 2.
    Matsuo T, Suzuki S, Matsuo M, et al. Preexisting antibodies to platelet factor 4-heparin complexes in patients with acute coronary syndrome who have no history of heparin exposure. Pathophysiol Haemost Thromb. 2005;34(1):18–22.PubMedCrossRefGoogle Scholar
  3. 3.
    Tatarewicz SM, Juan G, Swanson SJ, et al. Epitope characterization of pre-existing and developing antibodies to an aglycosylated monoclonal antibody therapeutic of G1m17,1 allotype. J Immunol Methods. 2012;382(1–2):93–100.PubMedCrossRefGoogle Scholar
  4. 4.
    Watanabe M, Uchida K, Nakagaki K, et al. High avidity cytokine autoantibodies in health and disease: pathogenesis and mechanisms. Cytokine Growth Factor Rev. 2010;21:263–73.PubMedCrossRefGoogle Scholar
  5. 5.
    Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med. 2008;358:1109–17.PubMedCrossRefGoogle Scholar
  6. 6.
    Weeraratne D, Chen A, Pennucci JJ, et al. Immunogenicity of panitumumab in combination chemotherapy clinical trials. BMC Clin Pharmacol. 2011;11:17. doi:10.1186/1472-6904-11-17.PubMedCrossRefGoogle Scholar
  7. 7.
    Singla NK, Gasparis AP, Ballard JL, et al. Immunogenicity and safety of re-exposure to recombinant human thrombin in surgical hemostasis. J Am Coll Surg. 2011;213(6):722–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Xue L, Fiscella M, Rajadhyaksha M, et al. Pre-existing biotherapeutic-reactive antibodies: survey results within the American Association of Pharmaceutical Scientists. AAPS J. 2013. doi: 10.1208/s12248-013-9492-4Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2013

Authors and Affiliations

  1. 1.Pharmacokinetics, Dynamics & Metabolism (PDM-NBE), Immunogenicity SciencesPfizer Inc.AndoverUSA

Personalised recommendations